News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diosynth Biotechnology (Research Triangle Park) Announces Agreement with Talecris Biotherapeutics for Process Development and Clinical Production of Recombinant Plasminogen



4/2/2007 12:32:55 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Diosynth Biotechnology announced today that it has signed an agreement with Talecris Biotherapeutics for process development activities and cGMP production of clinical trial material for a unique form of recombinant Plasminogen. Recombinant Plasminogen is an intermediate material used in the manufacture of recombinant Plasmin, a second-generation therapy Talecris is developing for both ophthalmic and thrombolytic indications.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES